- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01654068
Conformal High Dose Intensity Modulated Radiation Therapy for Disease to Thoracic and Lumbar Spine
April 16, 2019 updated by: Ronald McGarry
Conformal High Dose Intensity Modulated Radiation Therapy for Asymptomatic Metastatic Disease to the Thoracic and Lumbar Spine
The purpose of this study is to determine if Conformal High Dose Intensity Modulated Radiation Therapy is an appropriate option for treating cancer that has spread to the spinal column.
This study involves patients who have been diagnosed with metastatic cancer to the thoracic and lumbar vertebral body levels and currently do not have symptoms caused from the area of concern.
The goal is to prove that this is not only a safe form of treatment, but that Conformal High Dose Intensity Modulated Radiation Therapy can reduce the risk of cancer coming back in the area that the investigators treat which may reduce the risk of developing symptoms like pain in the future.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histological confirmation of malignancy (non-small cell lung cancer, breast cancer (hormone refractory), prostate cancer (hormone refractory), lymphoma, renal cell carcinoma, myeloma by either biopsy or cytology of the primary or metastatic lesion.
- Patients must have radiological documentation of metastatic disease to the thoracic or lumbar spine including both positron emitted tomography (PET) or nuclear medicine bone scan (NMBS) and Magnetic Resonance Imaging (MRI) within 4 weeks prior to study entry.
- Patients with one to three spinal metastases to the thoracic or lumbar spine will be included.
- Spinal metastatic lesions should be limited to one vertebral body level or ≤ 6cm in greatest dimension.
- Tumors should not directly abut the spinal cord, and have at least 5mm separation from the spinal cord. For patients with tumors closer than 5mm, inclusion is permissible at the discretion of the treating radiation oncologist such that dosimetric review demonstrates that the total dose to spinal cord is within tolerable range of <10Gy to 10% partial volume or max point dose 18 Gy.
- Patients must be able to fit into either the Elekta Stereotactic Body Frame or the Elekta Stereotactic BodyFix immobilization device.
- Must be ≥ 18 years of age.
- ECOG status 0-2.
- Women of childbearing potential and male participants must use an effective contraception method. (Until at least 60 days following treatment.)
- Negative urine pregnancy test within at least one week before starting treatment in women of child-bearing age.
- Patients must sign a study-specific informed consent form.
Exclusion Criteria:
- Patients with evidence of spinal instability OR neurologic deficit resulting from bony compression of neurologic structures.
- Patients with other systemic illness, or have not recovered adequately from their primary treatment or who have evidence of progression of their current cancer prior to therapy that, in the investigator's opinion, would preclude their inclusion.
- Patient may not receive concomitant cytotoxic anti-neoplastic therapy during treatment. Patients may be allowed to use hormonal suppression therapy or bisphosphonates for hypercalcemia.
- Pregnant or lactating women.
- Any patient with symptoms of pain, compression fracture, neurologic deficit will not be included.
- Patients previously treated with radiation therapy to the thoracic or lumbar spinal levels of involved disease will not be included.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Radiation Therapy to Local Spine Metastasis
Conformal High Dose Intensity Modulated Radiation Therapy to a single asymptomatic local spine metastasis.
|
Conformal High Dose Intensity Modulated Radiation Therapy 14-16Gy single fraction dosing using 6MV photons
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to Any Skeletal Related Event
Time Frame: up to 24 months
|
Time to any skeletal related event most commonly symptomatic recurrence or progression with pain/neurologic impairment with evidence of radiographic progression (median local progression-free survival).
|
up to 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acute Radiation Toxicity
Time Frame: 90 days
|
The number of acute side effects of radiation therapy will be documented (≤ 90 days from start of radiation therapy)
|
90 days
|
Late Radiation Toxicity
Time Frame: 2 years
|
The number of late side effects of radiation therapy will be documented (> 90 days after the start of radiation therapy)
|
2 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ronald McGarry, M.D., University of Kentucky
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 9, 2009
Primary Completion (Actual)
April 22, 2016
Study Completion (Actual)
September 8, 2016
Study Registration Dates
First Submitted
July 17, 2012
First Submitted That Met QC Criteria
July 30, 2012
First Posted (Estimate)
July 31, 2012
Study Record Updates
Last Update Posted (Actual)
April 19, 2019
Last Update Submitted That Met QC Criteria
April 16, 2019
Last Verified
March 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MCC-09-RAD-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
Yes
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vertebral Metastasis
-
University of LouisvilleJames Graham Brown Cancer CenterTerminatedVertebral MetastasisUnited States
-
Axon srlRecruiting
-
DFINE Inc.Completed
-
Institut Cancerologie de l'OuestRecruiting
-
Istituto Clinico HumanitasTerminated
-
Sunnybrook Health Sciences CentreCompleted
-
Heidelberg UniversityUnknown
-
Heidelberg UniversityUnknownVertebral Bony MetastasesGermany
-
Heidelberg UniversityUnknownVertebral Bony MetastasesGermany
-
Istituto Ortopedico RizzoliCompleted
Clinical Trials on Conformal High Dose Intensity Modulated Radiation Therapy
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingMetastatic Malignant Female Reproductive System NeoplasmUnited States
-
Virginia Commonwealth UniversityCompletedAdenocarcinoma of the ProstateUnited States
-
NRG OncologyNational Cancer Institute (NCI); Radiation Therapy Oncology GroupActive, not recruitingExtensive Stage Small Cell Lung Carcinoma | Limited Stage Small Cell Lung CarcinomaUnited States, Canada
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedBrain Tumor | Central Nervous System TumorUnited States, Canada, Australia, Puerto Rico, Switzerland, New Zealand
-
National Cancer Institute (NCI)CompletedGliosarcoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Diffuse Intrinsic Pontine GliomaUnited States, Canada, Australia
-
UNICANCERActive, not recruiting
-
M.D. Anderson Cancer CenterCompletedLung CancerUnited States
-
Emory UniversityTerminatedBladder Cancer | Stage III Bladder Cancer | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Squamous Cell Carcinoma of the BladderUnited States
-
Massachusetts General HospitalM.D. Anderson Cancer Center; National Cancer Institute (NCI)Active, not recruitingChordoma of Sacrum | Chordoma of Spine | Chordoma of Base of Skull | Chondrosarcoma of the Spine | Chondrosarcoma of the SacrumUnited States